Tevogen Announces Formation of a Healthcare Services Initiative

About this update from Tevogen Bio Holdings Inc.

WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company’s evolution into a broader, revenue-generating healthcare enterprise. The initiative will be led on an interim basis by William Keane, Tevogen’s Vice President of Strategic Initiatives. The healthcare services initiative may include, if consummated, the Company’s currently evaluated acquisition opportunities involving a Management Services Organization (“MSO”) and a Contract Research Organization (“CRO”). These potential acquisitions could help pave the Company’s path toward approximately $100 million in combined annual revenue, while advancing Tevogen’s mission to improve affordability and access across healthcare. “Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to building revenue-generating capabilities that may support long-term financial self-sufficiency,” said Kirti Desai, Chief Financial Officer at Tevogen. “With approximately $100 million in potential combined annual revenue under evaluation, we believe these opportunities could represent an important step toward strengthening the Company’s financial foundation while remaining aligned with our mission to make healthcare more affordable and accessible.” The healthcare services initiative is intended to complement the Company’s existing biotechnology and artificial intelligence initiatives by expanding its potential healthcare infrastructure capabilities and supporting future growth opportunities. The Company emphasized that any acquisition-related decisions will continue to be guided by strategic fit, long-term value creation, and disciplined stewardship of Tevogen’s capital structure. About Tevogen Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system. Tevogen Bio, the company’s lead initiative, has completed...

View stock analysis, news, and events for Tevogen Bio Holdings Inc.